U.S. markets closed
  • S&P Futures

    4,550.50
    +6.00 (+0.13%)
     
  • Dow Futures

    35,429.00
    +40.00 (+0.11%)
     
  • Nasdaq Futures

    15,609.00
    +21.75 (+0.14%)
     
  • Russell 2000 Futures

    2,254.90
    +5.40 (+0.24%)
     
  • Crude Oil

    80.80
    -1.86 (-2.25%)
     
  • Gold

    1,803.90
    +5.10 (+0.28%)
     
  • Silver

    24.16
    -0.04 (-0.15%)
     
  • EUR/USD

    1.1612
    +0.0005 (+0.05%)
     
  • 10-Yr Bond

    1.5290
    -0.0900 (-5.56%)
     
  • Vix

    16.98
    +1.00 (+6.26%)
     
  • GBP/USD

    1.3743
    +0.0000 (+0.00%)
     
  • USD/JPY

    113.5980
    -0.2120 (-0.19%)
     
  • BTC-USD

    58,980.75
    -1,538.62 (-2.54%)
     
  • CMC Crypto 200

    1,413.02
    -61.31 (-4.16%)
     
  • FTSE 100

    7,253.27
    -24.35 (-0.33%)
     
  • Nikkei 225

    28,825.62
    -272.62 (-0.94%)
     

Is Cassava Sciences Back in the Game?

·4 min read
Is Cassava Sciences Back in the Game?
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Last week, biotech Cassava Sciences (NASDAQ: SAVA) published topline interim-analysis data for simufilam, a potential treatment for Alzheimer's disease. Unfortunately, these developments do not paint a clear path to victory, but instead, they raise more perplexing questions about its science. In the study, the first 50 Alzheimer's patients with mild to moderate disease who received simufilam for a period of 12 months saw their cognition improve by an average of 3.2 points on the Alzheimer's Disease Assessment Cognitive Subscale (ADAS-COG) from baseline.